Eisai Co. Ltd. and Biogen Inc. should continue with their Phase III trial of elenbecestat in early Alzheimer’s disease, according to the data safety and monitoring board for the program. The DSMB recommendation came after a review of safety data, including the potential for decline in cognition.
The news will be a relief for the partners, which on March 21, 2019 announced the discontinuation of their most...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
